228 related articles for article (PubMed ID: 7531846)
1. Comparison of the effects of new specific azasteroid inhibitors of steroid 5 alpha-reductase on canine hyperplastic prostate: suppression of prostatic DHT correlated with prostate regression.
Cohen SM; Werrmann JG; Rasmusson GH; Tanaka WK; Malatesta PF; Prahalada S; Jacobs JG; Harris G; Nett TM
Prostate; 1995 Feb; 26(2):55-71. PubMed ID: 7531846
[TBL] [Abstract][Full Text] [Related]
2. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
Habib FK; Ross M; Tate R; Chisholm GD
Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
[TBL] [Abstract][Full Text] [Related]
3. Quantitative evaluation of glandular and stromal compartments in hyperplastic dog prostates: effect of 5-alpha reductase inhibitors.
Laroque PA; Prahalada S; Molon-Noblot S; Cohen SM; Soper K; Duprat P; Peter CP; van Zwieten MJ
Prostate; 1995 Sep; 27(3):121-8. PubMed ID: 7567690
[TBL] [Abstract][Full Text] [Related]
4. Effects of competitive and noncompetitive 5α-reductase inhibitors on serum and intra-prostatic androgens in beagle dogs.
Zhao XF; Yang Y; Wang W; Qiu Z; Zhang P; Wang B
Chin Med J (Engl); 2013 Feb; 126(4):711-5. PubMed ID: 23422194
[TBL] [Abstract][Full Text] [Related]
5. Magnetic resonance imaging of the efficacy of specific inhibition of 5 alpha-reductase in canine spontaneous benign prostatic hyperplasia.
Cohen SM; Taber KH; Malatesta PF; Shpungin J; Berman C; Carlin JR; Werrmann JG; Prahalada S; Bryan RN; Cordes EH
Magn Reson Med; 1991 Sep; 21(1):55-70. PubMed ID: 1719333
[TBL] [Abstract][Full Text] [Related]
6. Castration-like effects on the human prostate of a 5 alpha-reductase inhibitor, finasteride.
Geller J; Sionit L
J Cell Biochem Suppl; 1992; 16H():109-12. PubMed ID: 1283893
[TBL] [Abstract][Full Text] [Related]
7. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
[TBL] [Abstract][Full Text] [Related]
8. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
[TBL] [Abstract][Full Text] [Related]
9. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen.
Geller J
J Clin Endocrinol Metab; 1990 Dec; 71(6):1552-5. PubMed ID: 1699965
[TBL] [Abstract][Full Text] [Related]
10. MK-386, an inhibitor of 5alpha-reductase type 1, reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen.
Schwartz JI; Tanaka WK; Wang DZ; Ebel DL; Geissler LA; Dallob A; Hafkin B; Gertz BJ
J Clin Endocrinol Metab; 1997 May; 82(5):1373-7. PubMed ID: 9141518
[TBL] [Abstract][Full Text] [Related]
11. [Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia].
Bartsch G; Rittmaster RS; Klocker H
Urologe A; 2002 Sep; 41(5):412-24. PubMed ID: 12426858
[TBL] [Abstract][Full Text] [Related]
12. Changes in the Serum Prostatic Biomarkers During the Treatment of Benign Prostatic Hyperplasia with a 5alpha-reductase Inhibitor: Finasteride.
Golchin-Rad K; Mogheiseh A; Nazifi S; Ahrari Khafi MS; Derakhshandeh N; Abbaszadeh-Hasiri M
Top Companion Anim Med; 2020 Mar; 38():100405. PubMed ID: 32115076
[TBL] [Abstract][Full Text] [Related]
13. Dihydrotestosterone concentration of beagle prostatic tissue: effect of age and hyperplasia.
Ewing LL; Berry SJ; Higginbottom EG
Endocrinology; 1983 Dec; 113(6):2004-9. PubMed ID: 6196180
[TBL] [Abstract][Full Text] [Related]
14. CGP 53153: a new potent inhibitor of 5alpha-reductase.
Häusler A; Allegrini PR; Biollaz M; Batzl C; Scheidegger E; Bhatnagar AS
J Steroid Biochem Mol Biol; 1996 Feb; 57(3-4):187-95. PubMed ID: 8645628
[TBL] [Abstract][Full Text] [Related]
15. Prostatic involution in rats induced by a novel 5 alpha-reductase inhibitor, SK&F 105657: role for testosterone in the androgenic response.
Lamb JC; English H; Levandoski PL; Rhodes GR; Johnson RK; Isaacs JT
Endocrinology; 1992 Feb; 130(2):685-94. PubMed ID: 1733716
[TBL] [Abstract][Full Text] [Related]
16. Hormonal effects of turosteride, a 5 alpha-reductase inhibitor, in the rat.
di Salle E; Giudici D; Briatico G; Ornati G; Panzeri A
J Steroid Biochem Mol Biol; 1993 Nov; 46(5):549-55. PubMed ID: 8240976
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of MENT on primary cell cultures from benign prostatic hyperplasia and prostate carcinoma.
Mendoza P; Sánchez C; Contreras HR; Vergara J; Acevedo C; Cabezas J; Huidobro C; Noé G; Castellón EA
Int J Androl; 2009 Dec; 32(6):607-15. PubMed ID: 18637152
[TBL] [Abstract][Full Text] [Related]
18. Changes in dihydrotestosterone metabolism associated with the development of canine benign prostatic hyperplasia.
Isaacs JT; Coffey DS
Endocrinology; 1981 Feb; 108(2):445-53. PubMed ID: 6161001
[TBL] [Abstract][Full Text] [Related]
19. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia.
McConnell JD; Wilson JD; George FW; Geller J; Pappas F; Stoner E
J Clin Endocrinol Metab; 1992 Mar; 74(3):505-8. PubMed ID: 1371291
[TBL] [Abstract][Full Text] [Related]
20. The clinical development of a 5 alpha-reductase inhibitor, finasteride.
Stoner E
J Steroid Biochem Mol Biol; 1990 Nov; 37(3):375-8. PubMed ID: 1701660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
